Chakrabarti S, Osman H, Collingham K, Milligan D W
Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
Bone Marrow Transplant. 2003 Mar;31(5):379-86. doi: 10.1038/sj.bmt.1703847.
Haemorrhagic cystitis (HC) is an important cause of morbidity following stem cell transplantation (SCT) and has been associated with polyoma virus infection. We studied the incidence and outcome of polyoma virus infection in 58 T-cell-depleted SCT patients. T-cell depletion was carried out using Campath-1H, either 10 or 20 mg in vitro (n=33) or 50 or 100 mg in vivo (n=25) following conventional (n=35) or nonmyeloablative conditioning (n=23). A total of 21 patients (36%) had polyoma viruria at a median of 35 days (5-114); 30% among patients receiving Campath in vitro and 44% among those given in vivo. The only risk factor for polyoma viruria was graft-versus-host disease GVHD grade >or=2. The onset of polyoma viruria coincided with Cytomegalovirus (CMV) reactivation in all six patients who reactivated both viruses. Prolonged viruria (defined as polyoma viruria >2 weeks) was documented in 10 patients (17%) and this was associated with GVHD >or=grade 2. HC occurred in four patients. Prolonged viruria was associated with HC only in patients receiving unrelated donor grafts following conventional conditioning. HC was not observed following nonmyeloablative conditioning despite a higher incidence of prolonged viruria. Thus, HC was uncommon in patients with polyoma viruria following T-cell depletion with Campath, particularly after reduced intensity conditioning.
出血性膀胱炎(HC)是干细胞移植(SCT)后发病的重要原因,并且与多瘤病毒感染有关。我们研究了58例T细胞去除的SCT患者中多瘤病毒感染的发生率和结局。采用Campath-1H进行T细胞去除,在传统预处理(n = 35)或非清髓性预处理(n = 23)后,体外使用10或20mg(n = 33)或体内使用50或100mg(n = 25)。共有21例患者(36%)出现多瘤病毒尿,中位时间为35天(5 - 114天);接受体外Campath治疗的患者中有30%,接受体内治疗的患者中有44%。多瘤病毒尿的唯一危险因素是移植物抗宿主病(GVHD)≥2级。在同时重新激活两种病毒的所有6例患者中,多瘤病毒尿的发生与巨细胞病毒(CMV)重新激活同时出现。10例患者(17%)记录到持续性病毒尿(定义为多瘤病毒尿>2周),这与GVHD≥2级有关。4例患者发生了HC。仅在接受传统预处理后接受无关供体移植物的患者中,持续性病毒尿与HC有关。尽管持续性病毒尿的发生率较高,但非清髓性预处理后未观察到HC。因此,在使用Campath进行T细胞去除后出现多瘤病毒尿的患者中,HC并不常见,尤其是在减低强度预处理后。